Phase 2 represents the biggest attrition point in drug development, with only 28% of programs successfully advancing to Phase 3 according to 10-year Citeline data. The stakes for protocol quality have never been higher. Recent Tufts CSDD benchmarking reveals that the time to implement a protocol amendment has nearly tripled over the past decade, now averaging 260 days from identification to final ethics approval. For Phase 2 trials, that disruption can shift program timelines by a year or more.
The regulatory landscape has evolved significantly. ICH E6(R3), finalized in January 2025 and adopted by FDA in September 2025, restructured GCP around quality by design and risk-proportionate oversight. ICH M11 CeSHarP, adopted in November 2025, introduced standardized protocol structure to enable electronic exchange across sponsors, investigators, and regulators. These aren't just administrative changes. They reflect recognition that many protocol failures are execution failures that start with documents burying critical information.
Phase 2 protocols must answer harder questions than Phase 1: Does the drug work in patients? What dose moves forward? Is the primary endpoint sensitive enough? A flawed Phase 2 protocol doesn't just harm the current trial, it produces data that cannot support Phase 3 design, forcing sponsors into costly second studies or underpowered pivotal programs.